| EN
澳门PG电子游戏APP官方网站 Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D. We are committed to "providing today's patients with medicines of the future" across the following core therapeutic areas: oncology, central nervous system, autoimmunity and anti-infection. Furthermore, we are also actively expanding our presence in disease areas with significant clinical needs in the future.
Our industry-leading capabilities and commitment to synergistic innovation have also enabled various strategic collaborations and we are seen as partner of choice by innovative biopharmaceutical companies, medical institutes, and research teams in China and globally.

Milestones

  • 1995

  • 2001

  • 2003

  • 2006

  • 2007

  • 2013

  • 2015

  • 2018

  • 2019

  • 2020

  • 2021

  • 2022

  • 2023

  • established Jiangsu 澳门PG电子游戏APP官方网站, engaging in the sales, marketing and distribution of pharmaceuticals

  • cquired a controlling interest in Hainan 澳门PG电子游戏APP官方网站 and manufacturing capabilities of pharmaceuticals, built our own research and development team

  • acquired the entire equity interest in 澳门PG电子游戏APP官方网站 Dongyuan, established postdoctoral research station (博士后科研工作站)

  • acquired a controlling interest in Shandong 澳门PG电子游戏APP官方网站

  • became the first bio and chemical pharmaceutical company in China to be listed on the NYSE

  • completed the privatization

  • established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (转化医学与创新药物国家重点实验室) approved by the Ministry of Science and Technology

  • Shanghai R&D center established

  • Boston Innovation Center

  • Orencia® approved
    Sanbexin® approved
    Listed on the Hong Kong Stock Exchange

  • Enweida® approved
    Beijing Innovation Center

  • Cosela® approved

  • Xiannuoxin®approved

  • established Jiangsu 澳门PG电子游戏APP官方网站, engaging in the sales, marketing and distribution of pharmaceuticals
  • cquired a controlling interest in Hainan 澳门PG电子游戏APP官方网站 and manufacturing capabilities of pharmaceuticals, built our own research and development team
  • acquired the entire equity interest in 澳门PG电子游戏APP官方网站 Dongyuan, established postdoctoral research station (博士后科研工作站)
  • acquired a controlling interest in Shandong 澳门PG电子游戏APP官方网站
  • became the first bio and chemical pharmaceutical company in China to be listed on the NYSE
  • completed the privatization
  • established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (转化医学与创新药物国家重点实验室) approved by the Ministry of Science and Technology
  • Shanghai R&D center established
  • Boston Innovation Center
  • Orencia® approved
    Sanbexin® approved
    Listed on the Hong Kong Stock Exchange
  • Enweida® approved
    Beijing Innovation Center
  • Cosela® approved
  • Xiannuoxin®approved

Management Team

Ren Jinsheng

Chairman of the Board and
Chief Executive Officer

Tang Renhong, PhD

Executive Director of 澳门PG电子游戏APP官方网站
Chairman of the Board and CEO of 澳门PG电子游戏APP官方网站 Zaiming

Wan Yushan

Executive Director and
Chief Financial Officer

Wang Xi

Executive Director and Vice President

Bijoyesh Mookerjee, MD

Chief Medical Officer, Oncology

Zhou Gaobo

Chief Investment Officer

Tamas Oravecz, PhD

Senior Vice President
CSO of 澳门PG电子游戏APP官方网站, U.S.

Andrew Zhu

Chief Operating Officer of 澳门PG电子游戏APP官方网站 Zaiming

Danny Chen, PhD

Senior Vice President

Mission

Providing Today’s Patients with Medicines of the Future

Core values

PATIENT FIRST
JOINT EFFORT
INTEGRITY
EXCELLENCE

澳门PG电子游戏APP官方网站 CI

  • The name “澳门PG电子游戏APP官方网站” comes from the word “sincere”, which embodies our main principle of treating people with sincerity.
  • On the left side of our logo is 澳门PG电子游戏APP官方网站r running against the wind, representing the spirit of unremitting endeavor and the encourage to pursue excellence.
  • The color green symbolizes life, health and vitality.